Enliven Therapeutics, Inc. 4

CFO Benjamin Hohl sold 6,018 shares of Enliven Therapeutics, Inc. Common Stock on August 17, 2026 under a Rule 10b5-1 plan for total proceeds of about $351K, leaving him with 40,036 shares owned.

On August 17, 2026, Enliven Therapeutics, Inc. Chief Financial Officer Benjamin Hohl sold a total of 6,018 shares of the company’s Common Stock in two open-market transactions executed under a pre-established Rule 10b5-1 trading plan adopted on March 18, 2026. The sales consisted of 4,630 shares at a weighted average price of approximately $58.35 per share and 1,388 shares at a weighted average price of approximately $59.35 per share, for total proceeds of roughly $350,800. Following these sales, Hohl beneficially owned 40,036 shares of Enliven Therapeutics Common Stock, some of which are represented by restricted stock units that vest over time, indicating he retains a meaningful ongoing equity stake despite the planned diversification.

Filing Facts

CIK

1672619

Ticker

ELVN

Form

4

Source Type

fda

Accession

0001882764-26-000007

Alert Tier

6